Oncology Devices Market Report 2026

Oncology Devices Market Overview

• Oncology Devices market size has reached to $177.72 billion in 2025 • Expected to grow to $397.27 billion in 2030 at a compound annual growth rate (CAGR) of 17.3% • Growth Driver: Rising Chemotherapy Demand Driving Growth Of The Market Due To the Expanding Global Cancer Burden • Market Trend: Next-Generation Oncology Technologies Enhancing Surgical And Radiotherapy Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oncology Devices Market?

Oncology devices are medical instruments and technologies used in the diagnosis, treatment, and management of cancer. These devices are essential for detecting cancer early, monitoring its progression, delivering targeted treatments, and improving patient outcomes. They play a crucial role in various stages of cancer care, from screening and diagnosis to treatment and recovery. The main device types of oncology devices are brachytherapy devices and endoscopic devices. Endoscopic devices are medical devices used in the diagnosis, management, and treatment of cancer. It is used to look internally at a body cavity or organ. These are used in various therapies such as chemotherapy, hormone therapy, biotherapy/immunotherapy, and radiation therapy that are used by various end-users such as hospitals, cancer research institutes, and others.

What Is The Oncology Devices Market Growth Forecast?

The oncology devices market size is expected to see rapid growth in the next few years. It will grow to $397.27 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to increasing adoption of personalized cancer treatment devices, rising investments in oncology infrastructure, expansion of outpatient cancer treatment facilities, growing use of AI-driven diagnostic tools, increasing focus on precision oncology solutions. Major trends in the forecast period include increasing adoption of advanced cancer diagnostic devices, rising use of image-guided oncology therapies, growing integration of minimally invasive cancer treatment tools, expansion of precision radiation therapy equipment, enhanced focus on early cancer detection.

Global Oncology Devices Market Segmentation

1) By Device Type: Brachytherapy Devices, Endoscopic Devices 2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radition Therapy 3) By End User: Hospitals, Cancer Research Institutes, Other End Users Subsegments: 1) By Brachytherapy Devices: Afterloaders (High-Dose Rate (HDR) And Low-Dose Rate (LDR)), Applicators, Seeds, Accessories 2) By Endoscopic Devices: Endoscopes (Flexible, Rigid, Capsule), Endoscopic Ultrasound Systems, Endoscopic Accessories

What Is The Driver Of The Oncology Devices Market?

The increasing demand for chemotherapy is expected to propel the growth of the oncology devices market going forward. Chemotherapy is a cancer treatment that uses powerful drugs to destroy rapidly dividing cells, slowing or stopping the growth and spread of tumors. The demand for chemotherapy is rising due to the growing incidence of cancer worldwide because more diagnosed cases increase the need for effective, widely accessible treatments that can target diverse cancer types and stages. Oncology devices support chemotherapy by enabling safer, more precise drug delivery and monitoring, which enhances treatment effectiveness and patient outcomes. For instance, in January 2025, according to the U.S. National Cancer Institute, a U.S.-based federal cancer research agency, the number of new cancer cases in the United States is projected to reach 2.04 million, up from 1.96 million in 2023, highlighting the rising need for chemotherapy administration systems. Therefore, the increasing demand for chemotherapy is driving the growth of the oncology devices industry.

Key Players In The Global Oncology Devices Market

Major companies operating in the oncology devices market are Eckert & Ziegler BEBIG GmbH, Oncura Inc., GE Healthcare, Medtronic plc, Varian Medical Systems Inc., Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, IBA Group, Biogenex Laboratories, Becton Dickinson and Company, Siemens Healthineers, Philips Healthcare, Hologic Inc., IBA AG, ViewRay Inc., Canon Medical Systems Corporation, Brainlab, PerkinElmer, RaySearch Laboratories, Mevion Medical Systems, Vision RT, IsoRay, RefleXion Medical, Alpha Tau Medical, Nanobiotix, Mirada Medical Ltd., Navidea Biopharmaceuticals Inc.

Global Oncology Devices Market Trends and Insights

Major companies operating in the oncology devices market are focusing on developing advanced, precision-driven solutions to improve treatment accuracy, patient safety, and clinical workflow efficiency. These innovations emphasize minimally invasive technologies, enhanced visualization, and real-time therapy optimization to support better outcomes across various cancer types. For instance, in April 2025, ZEISS, a Germany-based medical technology company, received FDA 510(k) clearance for its INTRABEAM 700 system, a next-generation robotic-assisted intraoperative radiotherapy (IORT) platform designed for targeted radiation delivery in neuro-oncology and breast cancer procedures. The system offers greater precision, streamlined ergonomics, and improved integration into surgical workflows, enabling clinicians to administer localized radiation during surgery while minimizing exposure to surrounding healthy tissue. By incorporating cutting-edge imaging, robotics, and treatment-planning capabilities, the INTRABEAM 700 enhances therapeutic accuracy, supports faster clinical decision-making, and aligns with the industry’s shift toward technologically advanced, patient-centric oncology care.

What Are Latest Mergers And Acquisitions In The Oncology Devices Market?

In March 2024, Halma PLC, a UK-based life-saving technology companies that prevent injuries, saves lives, and protects people and assets acquired Rovers Medical Devices B.V for $93.5 million. With this acquisition, Halma PLC aims to broaden its market reach in women's health and strengthen its position in cancer diagnostics. Rovers Medical Devices B.V. is a Netherlands-based company that designs, develops, and manufactures cancer-screening medical devices.

Regional Outlook

North America was the largest region in the oncology devices market in 2025. Asia-Pacific was the second-largest region in the oncology devices market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Oncology Devices Market?

The oncology devices market consists of sales of brachytherapy devices and endoscopic devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.